VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 75 filers reported holding VAXCYTE INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,712,582 | -11.0% | 210,133 | -12.8% | 0.00% | 0.0% |
| Q2 2023 | $12,040,683 | +13.1% | 241,103 | -15.1% | 0.00% | 0.0% |
| Q1 2023 | $10,648,404 | -25.1% | 284,109 | -4.2% | 0.00% | -50.0% |
| Q4 2022 | $14,222,882 | +456.5% | 296,619 | +178.6% | 0.00% | – |
| Q3 2022 | $2,556,000 | +22.0% | 106,455 | +10.5% | 0.00% | – |
| Q2 2022 | $2,095,000 | +125.5% | 96,304 | +150.3% | 0.00% | – |
| Q1 2022 | $929,000 | -48.0% | 38,478 | -48.7% | 0.00% | – |
| Q4 2021 | $1,785,000 | +149.3% | 75,067 | +165.9% | 0.00% | – |
| Q3 2021 | $716,000 | -59.5% | 28,233 | -64.1% | 0.00% | – |
| Q2 2021 | $1,770,000 | +81.9% | 78,611 | +59.6% | 0.00% | – |
| Q1 2021 | $973,000 | +946.2% | 49,267 | +1297.2% | 0.00% | – |
| Q4 2020 | $93,000 | -49.2% | 3,526 | -4.8% | 0.00% | – |
| Q3 2020 | $183,000 | +2950.0% | 3,705 | +1752.5% | 0.00% | – |
| Q2 2020 | $6,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |